reSee.it - Tweets Saved By @catranchdream
@catranchdream - catranchdream🇨🇦🩸😤
Professor Angus Dalgleish (Oncologist) Sounds The Alarm: Covid Boosters Are Causing Cancer https://t.co/EbmALHGLS1
Video Transcript AI Summary
Patients with melanoma who received booster vaccines are experiencing relapses, some quite aggressive, requiring systemic therapy. Other individuals without melanoma are also reporting new health issues post-booster, including leukemias, lymphomas, and myeloma. These cases suggest a potential link between booster vaccines and health problems, prompting a call to investigate further and consider halting booster shots.
Full Transcript
Speaker 0: Patients of melanoma who've been stable, stage IV disease. They've had very good immunotherapy or other treatments. And I've been reviewing them from 5 to 20 years, I've noticed that I have now over 6, possibly 7 or even an 8th yesterday who've clearly relapsed following the booster vaccine. At first, we didn't put the 2 together. But when patients said, I felt awful awful since the vaccine.
I've just been drained. They describe symptoms of like a long COVID. And the next thing we know, 2, 3 weeks, couple of months later, they've got clear evidence of relapse. And these relapses are quite aggressive. They're not a gentle relapse.
They're relapses that are requiring systemic therapy as opposed to a little nodule that requires surgical excision. But it's not just this. I'm now very much aware in my own circle of many people who are having they haven't got melanoma, but they've never had anything before, they've got lumps and bumps, and they're not feeling well. And 2 people I have interviewed at great length, they all put it down to feeling awful after their booster. They were fine with the first two vaccines or just had shivers, flu, etcetera.
But they've described being very tired, very fatigued, wanted to stay in bed. And this has dragged on to the point where they've gone to the doctor, and they've had blood counts and investigations. And I now know 7 of them. 2 of them are leukemias, and the others have lymphomas. And one of them has a very bad myeloma, which he was absolutely sure was instigated by the booster as he developed the dreadful symptoms.
So really, I want to bring to everybody's attention that I think this does not look like a coincidence to me. And we nearly we need to join forces and see if this is a real effect. And if it is, we must stop all the boosters immediately. Thank you.
@catranchdream - catranchdream🇨🇦🩸😤
Pfizer Confesses To FDA That It Really Doesn’t Know How The COVID-19 Vaccine Works
Video Transcript AI Summary
The speaker discusses the effectiveness of the vaccine in terms of producing an immune response and the severity of breakthrough cases. They mention that there was no significant difference in the severity of illness between those who received the vaccine and those in the placebo group. The advantage of the vaccine is preventing infection in the first place. The speaker also addresses the dosing in terms of micrograms and mentions that the results show low reactogenicity and a comparable immune response. They mention that the amount of protein produced by the mRNA and its persistence is an interesting question worth pursuing. Another speaker adds that the two mRNA vaccines are different and have optimized the expression of antigens.
Full Transcript
Speaker 0: How should we think of micrograms in terms of the amount of spike protein that's produced by the cells? Can you kind of clarify that?
Speaker 1: Obviously, we don't have a complete understanding of the nature of the way that the vaccine works in terms of producing immune response. Obviously, we don't have a complete understanding of the nature of the way that the vaccine works in terms of producing immune response.
Speaker 2: I would also like you to talk a little bit about your breakthrough disease and see if there was any differences in the severity of disease and those who had Received vaccine versus those who, were in the placebo group? I'm asking about the disease profiles in those 2 groups.
Speaker 1: The nature of severity of the illness, we've actually included in your briefing document. And there was really, No difference. If we looked at all the cases, I'm talking about based on the number of symptoms that they had, in terms of breakthrough, compared to placebo, whether it was, you know, 1, 2, 3, or or more symptoms, there really was not a dime's worth of difference, between the, the respective groups, Between those that break through that receive vaccine versus placebo. So that gave us confidence in that larger, you know, sort of, population of cases that we have that, that? That does not appear to be an issue.
Speaker 2: It also doesn't seem to, if the disease is the same in the placebo group, it didn't show a necessary advantage of the vaccine, I guess was what I Well,
Speaker 1: I guess the advantage of the vaccine is you're preventing the infection in the 1st place. Right?
Speaker 2: I get that.
Speaker 1: You know, that's the big advantage. Right? And but the the good news is it doesn't Seemed to make the disease worse if, in fact, you've received the vaccine. And I think that's an important thing and why we looked at it. Thank you.
And but the good news is it doesn't seem to make the disease worse.
Speaker 0: I guess I'm a little bit confused about, This dosing in terms of micrograms because your dosing is 3 micrograms, the Moderna dosing is 25 micrograms. Clearly, we're thinking in terms of micrograms the way we would think of proteins as a way of inducing an immune response. And yet the purpose of mRNA is to induce protein Production. So is your mRNA just more efficient at making cells produce protein? Or how should we think of Micrograms, in terms of the amount of spike protein that's produced by the cells, can you kind of clarify that?
Yeah.
Speaker 1: I'll leave to Moderna to describe the nature of how they, address their vaccine dosage. But I think Obviously, we don't have a complete understanding of the nature of the way that the vaccine works in terms of producing immune response. So you have to go by the results. And the results are that in the setting of giving a 3 microgram dose, we had low reactogenicity compared to placebo. And after a third dose, Just as in adults at higher doses, we're getting an immune response that's comparable.
It may well be the children we've seen certainly That we are able to go down to a lower dose in children, and the expectation is perhaps they have a more robust response. That seems to be the case based on giving a 10 microgram dose to 5 to 11s and 3 micrograms to younger.
Speaker 0: But have you ever measured the amount of protein that's produced as a result of the mRNA and how many cells are producing it and how persistent that production is for a given microgram of mRNA? That's a pretty broad question. But, you know, that's
Speaker 1: I think that's obviously, you know, an interesting question to better understand the mechanism. And I would say Yeah. It's somewhat academic in the setting of what we're trying to achieve here in terms of getting an immune response and a safety profile. It's satisfactory, but worthwhile for people to pursue.
Speaker 0: Okay. Thank you.
Speaker 1: Let me just Doctor. Jansen, the head of vaccine research and development, would like to make a comment about that last question. Very brief.
Speaker 3: Thank you, Bill. I think one important consideration for the answer to the question that was just posed is that The 2 mRNA vaccines are not created equal. They're actually very different vaccine. They use the same platform. They have different formulations.
And so I think that's important to recognize. And the 2nd piece is that we of course have optimized the vaccine for optimal, expression Of the antigens themselves. And if you ask the question, is there a large number of protein molecules expressed in the cells? The answer is yes. Thank
Speaker 1: you. Thank you both. Doctor. Cohen, final question.
Speaker 3: That we, of course, have optimized the vaccine for optimal, expression of the antigens themselves. And if you ask the question, Is there large number of, protein molecules expressed in the cells? The answer is yes.